CURRENT MANAGEMENT OF GOUT

被引:0
|
作者
Miguel, Claudia [1 ]
Mediavilla, Maria Jesus [1 ]
机构
[1] Inst Portugues Reumatol, Lisbon, Portugal
来源
ACTA MEDICA PORTUGUESA | 2011年 / 24卷 / 05期
关键词
URIC-ACID; CARDIOVASCULAR-DISEASE; XANTHINE-OXIDASE; HYPERURICEMIA; ALLOPURINOL; FEBUXOSTAT; ARTHRITIS; INHIBITOR; TRIAL; INDOMETHACIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CURRENT MANAGEMENT OF GOUT Gout, one of the most prevalent rheumatic diseases in the world, results from deposition of uric acid crystals in several locations, particularly in joints, subcutaneous tissues and kidney. The classical treatments, although effective, are often poorly tolerated or contraindicated. Recently, new drugs have emerged for the treatment of hyperuricemia and gout, including febuxostat and uricase, which proved to be quite promising. Some drugs already used in other diseases, such as losartan, atorvastatin, fenofibrate and amlodipine also seem to have a role in monitoring the serum uric acid. This article reviews the pathophysiology, clinical management and current therapeutic options for Hyperuricemia and Gout.
引用
收藏
页码:791 / 798
页数:8
相关论文
共 50 条